Human iPSC line GFM1SV.25 was generated from fibroblasts of a child with a severe mitochondrial encephalopathy associated with mutations in the GFM1 gene, encoding the mitochondrial translation elongation factor G1. Reprogramming factors OCT3/4, SOX2, CMYC and KLF4 were delivered using a non integrative methodology that involves the use of Sendai virus.
Resource table:
Name of stem cell line GFM1SV.25 
Resource details
The generation of the human iPSC line, GFM1SV.25, was carried out using non-integrative Sendai viruses containing the reprogramming factors, OCT3/4, SOX2, CMYC, KLF4 (Takahashi et al., 2007) . For this purpose, fibroblasts from a described patient with a severe mitochondrial encephalopathy were obtained (Brito et al., 2015) . The patient's fibroblasts carried two inherited heterozygous mutations in the GFM1 gene (c.1404delA; p.Gly469Valfs*84 and c.2011CNT; p.Arg671Cys). The presence of these mutations in the iPSC line was evaluated and confirmed by Sanger sequencing (Fig. 1A) . GFM1SV.25 iPSC colonies displayed a typical ES-like colony morphology and growth behavior (Fig. 1B) and they stained positive for alkaline phosphatase activity (Fig. 1C) . We confirmed the clearance of the vectors and the exogenous reprogramming factor genes by RT-PCR after eight culture passages (Fig 1D) . The endogenous expression of the pluripotency associated transcription factors OCT4, SOX2, KLF4, NANOG, CRIPTO and REX1 was also evaluated by RT-PCR (Fig. 1E) . Immunofluorescence analysis revealed expression of transcription factors OCT4, NANOG, SOX2 and surface markers SSEA3, SSEA4, TRA1-60 and TRA1-81 characteristics of pluripotent ES cells (Fig. 1F) . Promoters of the pluripotency associated genes, OCT4 and NANOG, heavily methylated in the original fibroblasts were almost demethylated in the GFM1SV.25 line suggesting an epigenetic reprogramming to pluripotency (Fig. 1G) . The iPSC line has been adapted to feeder-free culture conditions and displays a normal karyotype (46, XX) after more than twenty culture passages (Fig. 1H) . We also confirmed by DNA fingerprinting analysis that the line Stem Cell Research 16 (2016) GFM1SV.25 was derived from the patient's fibroblasts (Fig. 1I) . Finally, the capacity of the generated iPSC line to differentiate into the three germ layers (endoderm, mesoderm and ectoderm) was tested in vitro using an embryoid body based assay (Fig. 1J ).
Materials and methods

Non-integrative reprogramming of mutant GFM1 fibroblasts into iPSC
All the experimental protocols included in the present study were approved by the Institutional Ethical Committee of the Autonoma University of Madrid according to Spanish and European Union legislation. Human fibroblasts from a described patient presenting with a severe mitochondrial encephalopathy associated with mutations in the GFM1 gene were used (Brito et al., 2015) . For this purpose tissue fragments were obtained from a skin biopsy of this patient after informed consent. These fragments were directly plated in a dish with DMEM high glucose with 10% defined fetal bovine serum (Hyclone), 2 mM GlutaMAX and 1× Penicillin-Streptomycin (Life Technologies). After 3-4 weeks, fibroblasts outgrowing from the biopsy pieces will cover most of the dish and were expanded at 37°C in 5% CO2 until the second passage. Subsequently, these fibroblasts were reprogrammed using the CytoTune-iPS 2.0 Sendai reprogramming kit following the instructions of the manufacturer. After eight passages of the iPSC line, silencing of the exogenous reprogramming factors genes and Sendai virus genome was confirmed by RT-PCR following the manufacturer's instructions. GFM1SV.25 was maintained and expanded both on feeder layers and on feeder-free layers. In the first case, irradiated human fibroblasts feeders with ES medium containing: Knockout DMEM (Life technologies), Knockout serum replacement 20%, (Life technologies), MEM non-essential amino acids solution 1 × (Life technologies), GlutaMAX 1 × (Life technologies), β-mercaptoethanol (100 μM), penicillin/streptomycin 1 × (Life technologies) and bFGF (4 ng/ml) (Miltenyi Biotec) were used. Subsequently, GFM1SV.25 was adapted and cultured in feeder-free conditions on matrigel (354277, Corning) with mTeSR1 medium (StemCell) following the recommendations of the manufacturer. For the propagation of the line, both enzymatic (dispase, collagenase IV and accumax) and mechanical procedures have been used.
Phosphatase alkaline analysis
The iPSC line GFM1SV.25 was seeded on a feeder layer plate. After seven days direct phosphatase alkaline activity was determined using the phosphatase alkaline blue membrane substrate solution kit (Sigma, AB0300) following the instructions of the manufacturer.
Mutation analysis
Total DNA from the patient's fibroblasts and iPSCs was extracted using a standard phenol-chloroform protocol. Subsequently, amplification by PCR of the GFM1 gene region containing the c.1404delA mutation (exon 12) and the c.2011C N T mutation (exon 16) was carried out using the following primers: For detection of the c.1404delA mutation (GFM1-12F: 5′-GAGTTAAGTCTTGGACTCTTG-3′ and GFM1-12R: 5′-GAAGCAGTAGACCACATCTG-3′). For detection of the c.2011CNT mutation (GFM1-16F: 5′-CAGGAAAAATGAGTCTAGGTC-3′ and GFM1-16R: 5′-CTTTTTAATTTGTCCATCTGTGC-3′) Following PCR amplification, direct sequencing of amplicons was performed on both strands in an ABI 3730 sequencer (Applied Biosystems; Foster City, CA) using a dye terminator cycle sequencing kit (Applera, Rockville, MD).
qPCR analyses
Total mRNA was isolated using TRIZOL and 1 μg was used to synthesize cDNA using the Quantitect reverse transcription cDNA synthesis kit. One μl of the reaction was used to quantify by qPCR the expression of the endogenous pluripotency associated genes (OCT4, SOX2, KLF4, NANOG, CRIPTO and REX1). Primers sequences were described by Aasen et al., 2008 . All the expression values were normalized to the GAPDH housekeeping gene. Plots are representative of at least three independent experiments.
Bisulfite pyrosequencing
Bisulfite modification of genomic DNA was performed with the EZ DNA Methylation-Gold kit (Zymo Research) following the manufacturer's instructions. The set of primers for PCR amplification and sequencing of NANOG and OCT4 were designed using the software PyroMark Assay Design (version 2.0.01.15; Qiagen): Forward-NANOG (5´-TAT TGG GAT TAT AGG GGT GGG TTA-3´), Reverse-NANOG (5´-[Btn]-CCC AAC AAC AAA TAC TTC TAA ATT CAC-3´), and sequencing primer S-NANOG (5´-ATA GGG GTG GGT TAT-3´); Forward-OCT4_prox (5´-GGG GTT AGA GGT TAA GGT TAG TG-3´), Reverse-OCT4_prox (5´-[Btn]-ACC CCC CTA ACC CAT CAC-3´), and sequencing primer SOCT4_prox (5´-GGG GTT GAG TAG TTT-3´); Forward-OCT4_dist (5´-TTT TTG TGG GGG ATT TGT ATT GA-3´), Reverse-OCT4_dist (5´-[Btn]-AAA CTA CTC AAC CCC TCT CT-3´), and sequencing primer S-OCT4_dist (5´-ATT TGT ATT GAG GTT TTG GA-3´). PCR was performed with primers biotinylated to convert the PCR product to single-stranded DNA templates, using the Vacuum Prep Tool. After PCR amplification, pyrosequencing reactions and methylation quantification were performed using PyroMark Q24 reagents, equipment and software (version 2.0.6; Qiagen), according to the manufacturer's instructions.
Karyotype analysis
Karyotype analyses of the iPSC line were carried out using cells with more than twenty culture passages. These cells were processed using standard cytogenetic techniques. Briefly, cells were treated with 10 μg/mL of Colcemid (Gibco) for 90 min at 37°C, trypsinized, treated with 0.075 M hypotonic KCl solution, and fixed with Carnoy's fixative. Cells were then dropped on a microscope glass slide and dried. Metaphase cells were G banded using Wright staining. At least 20 metaphases were karyotyped.
Immunofluorescence analysis
Cells were grown on 0.1% gelatin-coated P35 culture plates (81156, Ibidi) and fixed with 4% paraformaldehyde. The following antibodies for the staining were used: TRA-1-60 (Millipore; MAB4360; 1:150); TRA-1-81 (Millipore; MAB4381; 1:150); SOX2, (Thermo Scientific; PA116968; 1:100); NANOG (R&D Systems; AF1997; 1:25); SSEA-4 (Millipore; MAB4304; 1:10); SSEA-3 (Millipore; MAB4303; 1:10); OCT4 (Santa Cruz Biotechnology; Sc-5279; 1:100); neuron-specific class III beta-tubulin (Tuj1) (Sigma, T8660, 1:300), α-fetoprotein (AFP) (Sigma, WH0000174M1, 1:300), smooth muscle alpha actin (SMA) (Sigma, A2547, 1:400). Secondary antibodies used were all from the Alexa Fluor Series from Jackson Immunoresearch (all 1:500). Images were taken using a Zeiss confocal microscope.
In vitro differentiation assay
The in vitro pluripotency capacity of the iPSC line was tested by spontaneous embryoid body differentiation. For this purpose, iPSCs from a P100 plate with 80% of confluency were dissociated into a single cell suspension with accumax (SCR006, Millipore) and resuspended in 12 ml of mTeSR1 medium (Stemcell). Embryoid body formation was induced by seeding 120 μl of the iPSC suspension in each well of 96-well v-bottom low attachment plates and centrifuging the plates at 800 g for 10 min to aggregate the cells. After 2-3 days the embryoid bodies were transferred to an untreated P60 culture plate for 2-4 days. Subsequently, the embryoid bodies were transferred to 0.1% gelatin-coated P35 culture plates (81156, Ibidi) and cultured in differentiation medium (DMEM F12 supplemented with 20% fetal bovine serum, 2 mM glutamine, 0.1 mM β-mercaptoethanol, 1 × non essential amino acids and 1 × penicillin-streptomycin, all from Invitrogen) for 2-3 weeks to allow spontaneous endoderm formation. For mesoderm differentiation, iPSCs were maintained for 2-3 weeks in differentiation medium supplemented with 100 μM ascorbic acid (A4403, Sigma-Aldrich). For ectoderm differentiation, embryoid bodies were transferred to matrigel coated P35 culture plates and cultured in a special differentiation medium containing (50% DMEM F12, 50% neurobasal medium, 1× GlutaMAX, 1 × penicillin-streptomycin, non essential aminoacids, 0.1 mM 2-mercaptoethanol, 1 × N2 supplement and 1 × B27 supplement, all from Invitrogen). In all the cases, the medium was changed every other day.
DNA fingerprinting analysis
For DNA fingerprinting analysis, highly polymorphic regions containing short tandem repeated sequences of DNA have been evaluated. For this purpose, the following markers (D13S317, D7S820, VWA, D8S1179, D21S11, D19S433, D2S1338 and amelogenin for sex determination) have been amplified by PCR and analyzed by ABI PRISM 3100 Genetic analyzer and Peak Scanner v3.5 (Applied Biosystems). Primer sequences and PCR conditions are available upon request.
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